Clinical Report: HUCB-MSC Transplantation in Decompensated Liver Cirrhosis Patients
Overview
This retrospective cohort study evaluated the long-term outcomes of human umbilical cord blood-derived mesenchymal stem cell transplantation (HUCB-MSCT) in patients with decompensated liver cirrhosis (DLC). Results indicated improved survival rates in patients receiving HUCB-MSCT compared to those receiving standard care alone, with no significant increase in hepatocellular carcinoma incidence.
Background
Liver cirrhosis is characterized by fibrosis and pseudolobule formation, progressing slowly due to causes such as chronic alcoholism and viral hepatitis. Decompensated liver cirrhosis (DLC) often requires liver transplantation, but donor shortages and complications limit this option. Mesenchymal stem cell therapy, particularly using HUCB-MSCs, offers a less invasive alternative with potential to improve liver function. However, long-term efficacy and safety data remain limited.
Data Highlights
Group
Patients (n)
Overall Mortality (%)
Follow-up Duration
HUCB-MSCT (SCT)
36
Not specified in excerpt
Up to October 2021
Non-SCT
165 (matched to 72 post-PSM)
80.1%
Up to October 2021
Key Findings
HUCB-MSCT was associated with improved overall survival in patients with decompensated liver cirrhosis compared to standard treatment alone.
Propensity score matching balanced baseline characteristics between SCT and non-SCT groups, minimizing confounding factors.
No significant differences were observed in baseline clinical parameters except albumin levels before matching.
The incidence of hepatocellular carcinoma (HCC) post-transplantation did not increase, indicating safety of HUCB-MSCT.
Long-term follow-up extended up to nearly 8 years, providing valuable data on sustained outcomes.
Clinical Implications
HUCB-MSCT represents a promising adjunctive therapy for patients with decompensated liver cirrhosis, potentially improving survival without increasing cancer risk. Clinicians should consider HUCB-MSCT as a less invasive alternative to liver transplantation, especially in settings with limited donor availability. Long-term monitoring remains essential to confirm ongoing safety and efficacy.
Conclusion
HUCB-MSCT offers a viable and safe therapeutic option that improves long-term survival in patients with decompensated liver cirrhosis. Further prospective studies are warranted to consolidate these findings and optimize treatment protocols.
References
Liuzhou Hospital of Traditional Chinese Medicine, 2010-2013 -- Transplantation of Mesenchymal Stem Cells Derived from Human Umbilical Cord Blood in Patients with Decompensated Liver Cirrhosis
